Company ProfilePremium

Biogena Group Invest Ag

Company Profile Analysis

Ticker: BIO.VI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Biogena Group Invest Ag - Company showcase

Year Founded & Workforce

2020

Biogena Group Invest Ag logo

Biogena Group Invest Ag Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Biogena Group Invest Ag Overview

Data conflict on market capitalisation. The Wiener Börse instrument page carries a reference price of 41.55, a market cap of EUR 5.9m and a YTD of −26.96% [S3]. These are inconsistent with all 2026 press coverage, which reports prices of roughly EUR 3–5.40, YTD gains of 76–83%, and a market cap of EUR 17.72m in June 2026 [S11][S13]. The exchange page appears to be a stale or cached snapshot and is disregarded here.

Biogena Group Invest AG is a thinly capitalised listed holding vehicle whose value derives almost entirely from its minority interest in the BIOGENA operating structure. Press reporting puts that interest at roughly 4% of the Austrian sales company [S4]. BIOGENA itself, founded in Salzburg in 2006 by Dr. Albert Schmidbauer, is Austria's market leader in science-based premium micronutrient preparations made on the "pure substance" principle, meaning no colourants or preservatives. It produces in Austria and sells in more than 70 countries [S30][S7]. The group reported revenue of about EUR 124.9m and EBITDA of about EUR 19.1m in FY2024/25 [S12]. It is pursuing a "Vision 2030" target of roughly EUR 500m in revenue through direct-to-consumer channels, German expansion, flagship "PLAZA" health destinations, and a first entry into pharmacies [S8][S10][S12][S23]. For investors, Group Invest is now a merger-arbitrage instrument: each share converts into 0.879197 Biogena Good Vibes shares upon registration [S30].


What the listed entity does.

  • Biogena Group Invest AG is a holding company with no operations of its own. When it listed in 2020, the Vienna Stock Exchange described it as the issuer behind the central operating Biogena Group Invest GmbH & Co KG [S2].

  • When it moved up to direct market plus, the exchange described it as a shareholder in the Biogena Group [S1].

  • Regional press (July 2026) reports that it holds roughly four percent of the Austrian sales subsidiary. International distribution runs through Biogena International, which sits entirely within the new top holding [S4].

  • Its standalone income is therefore participation income. An aggregator shows revenue of about USD 402k, EBITDA of about USD 340k and net income of about USD 336k for the latest fiscal year (fiscal year unspecified; n/v) [S25].

What the BIOGENA GROUP does: company's own description. The group describes itself as follows:

  • An internationally oriented "361° Health" company exporting to more than 40 countries (older profile text) [S3]. More recent filings say more than 70 countries [S30].

  • Its core business is developing, producing and selling science-based premium micronutrient preparations under the pure-substance principle. It also positions itself as a knowledge and service partner in health, nutrition and well-being [S3].

  • Stated focus areas are iron, mineral and osteoporosis product innovations, and integrated solutions in occupational health promotion and diagnostics [S3][S30].

  • In its September 2026 listing communication, it calls itself a health group focused on micronutrients, diagnostics, prevention, longevity and personal health guidance. It develops and produces in Austria and sells through digital channels, medical and therapeutic partners, pharmacies, and its own stores and PLAZAs [S21].

Business model. BIOGENA is a vertically integrated brand owner covering the full value chain:

Revenue model mix.

  • The group does not publish a product vs. service vs. subscription split (n/d).

  • Analytically, revenue is predominantly product sales of supplements, sold both B2B2C through practitioners and D2C through stores and online.

  • Diagnostics, PLAZA treatments, Academy training and workplace health programmes add a smaller services layer.

  • BIOGENA ONE is positioned as a "daily health routine" [S12]. This suggests recurring purchase behaviour, but no subscription revenue is disclosed.

Customer types and end-markets.

  • More than 1 million customers in over 70 countries [S20].

  • Physicians and therapists using products alongside medical treatment or for prevention [S3].

  • Health-conscious consumers, including sports, aesthetics and longevity segments.

  • Corporate clients (occupational health) [S30].

  • Pet owners (BIOGENA PETS) [S33].

Independent characterisation. BIOGENA sits at the premium, practitioner-endorsed end of the European supplements market. It is distinctive in combining three things: owned manufacturing, a practitioner channel, and an experiential retail format (PLAZAs offering diagnostics, cold saunas and oxygen chambers [S6]). Its scale is small compared with multinational consumer-health players. Its growth record is unusually strong:

  • Average growth of roughly 27% a year since founding [S28].

  • +44% in FY2024/25 [S6].

Its capital-markets profile is unconventional:

  • Retail "community financing" since 2015: more than EUR 17m raised over 16 rounds from about 2,100 private investors [S19].

  • Retail growth bonds [S28][S8].

  • A retail-heavy share offering in 2026 [S20].

Strategy

Stated strategy themes. These are paraphrased from company communications [S12][S20][S23][S6]:

  1. Vision 2030. Grow revenue from approx. EUR 125m to approx. EUR 500m by 2030, without further production-capacity investment.

  2. Direct-to-consumer expansion and long-term customer loyalty. BIOGENA ONE positioned as a daily health routine.

  3. Germany as the primary international growth market. PLAZAs, sport sponsorship, pharmacy entry.

  4. Pharmacy channel entry (Austria, Germany, Italy) from October 2026. Pharmacies are described as the main sales channel for supplements, and one BIOGENA has so far been absent from.

  5. "Health destination" positioning. PLAZAs combining diagnostics, biohacking, longevity treatments and consultation.

  6. Science and quality leadership. In-house science team, "radical quality", Austrian production.

  7. Capital-markets ladder. The founder calls direct market plus a "good entry station" and signals larger ambitions. He has dismissed a foreign listing such as Nasdaq as not the benchmark.

  8. Founder-led family company with a long-term orientation.

Initiatives in the last 24 months.

Medium-term financial targets. FY2025/26 revenue approx. EUR 150m; approx. EUR 500m by 2030. Germany: EUR 58.0m to EUR 335.5m by FY2029/30. No margin, cash-flow or leverage targets are disclosed. Cost programmes: none disclosed.

Products & Services

BIOGENA does not publish a consolidated product catalogue with launch years and pricing in investor materials. The catalogue below lists offerings identifiable in public sources. Specifications and pricing for individual SKUs are n/d in investor disclosures.

Quality evidence:

  • Seven test wins in the Austrian "Market-Test" survey in 2025 [S6].

  • More than 90% of customers say they would recommend the brand (company claim) [S6].

Product Portfolio

Line / offeringDescriptionKey capabilities / specsTarget customerLaunch / latest versionPricing modelSource

Pure-substance micronutrient range (approx. 260 products)

Capsules/powders with no colourants or preservatives, made in Austria

Science-based formulation by an in-house team of about 25 scientists

Practitioners and patients; health-conscious consumers

Ongoing

Unit retail price (n/d)

[S28]

Iron preparations

Focus area for innovation

Iron supplementation

Patients with iron deficiency (via practitioners)

——

[S3][S30]

Mineral preparations

Focus area for innovation

Mineral supplementation

General / practitioner

——

[S3]

Osteoporosis products

Focus area for innovation

Bone health

Older adults, practitioners

——

[S3][S30]

BIOGENA ONE

Daily health routine product. New formula and brand identity in Aug 2026

All-in-one daily micronutrient

Mass-premium D2C

Relaunch 11 Aug 2026

—

[S12][S34]

BIOGENA Aesthetics

Beauty / skin micronutrients

—

Beauty-oriented consumers

——

[S28]

BIOGENA Sports

Performance and recovery products, supported by football partnerships

—

Athletes, clubs

——

[S28][S35]

BIOGENA PETS

Pet health and nutrition

Expanded via HEROSAN cooperation

Pet owners

Before Aug 2026

—

[S33]

BIOGENA PLAZAs

Large-format "medical wellness / day spa" health destinations

Diagnostics, biohacking, treatments, consultation, cold saunas, oxygen chambers

Affluent urban consumers

Düsseldorf Oct 2025 (1,000 m²); Munich Sep 2026; Frankfurt planned

Treatment/service fees (n/d)

[S6][S20]

Biogena Stores

Own retail stores

Consultation plus product sales

D2C

17 stores (date n/d)

Retail

[S3]

Webshop / e-commerce

Online D2C

+99% growth in Austria in FY2024/25

D2C

Ongoing

Retail

[S6]

MyBiogenaCoach

Digital advisory app

Personalised advice

D2C

Before Jan 2024

—

[S18]

Diagnostics

Lab / biomarker diagnostics

Health status testing

D2C, practitioners

——

[S20]

Workplace health promotion

Corporate health programmes

Integrated B2B solutions

Employers

—

Contract (n/d)

[S2][S30]

BIOGENA Academy

Knowledge transfer / training

Education

Practitioners, consumers

——

[S6]

Biogena Good Health World

Experience centre with own production, Koppl

Visitor experience plus manufacturing

Consumers, partners

Before Jan 2024

—

[S18]

Financial Narrative

BIOGENA GROUP (operating economics; FY = 1 Oct–30 Sep)

The group publishes headline revenue and EBITDA, plus prospectus-level figures for FY2024/25. Full five-year audited statements are not publicly available in a form verifiable here.

Sources:

  • Revenue and EBITDA [S12][S10].

  • EBIT and net income [S10][S9]. These were reported in press coverage of the prospectus/H1 period and attributed to the latest reported period. EBITDA of 19.08 matches the FY2024/25 figure.

  • Margins are calculated by the analyst.

Data conflicts.

  • FY2024/25 revenue is reported as EUR 124.9m (trend.at, prospectus-based [S12][S17]) and as approx. EUR 125m (ORF via [S36]). The Salzburg Chamber of Commerce (WKO) cites EUR 116m in a November 2025 article [S6]. The EUR 116m figure likely refers to a narrower perimeter (e.g., Biogena brand sales before consolidation) or a preliminary figure. The prospectus figure of EUR 124.9m is preferred.

  • FY2023/24 revenue is not directly disclosed. A 2024 bond marketing piece targeted approx. EUR 80m, which would be more than 25% growth on the prior year [S28]. Back-calculation from 124.9 at +44% implies approx. EUR 86.7m, while 116 at +44% implies approx. EUR 80.6m. The discrepancy is unresolved, so FY2023/24 is marked n/d.

Guidance and targets.

Sources: [S10][S17][S28][S12].

  • The FY2027/28 target of EUR 205m comes from 2024 bond marketing [S28] and appears to have been superseded by the more ambitious Vision 2030.

  • Vision 2030 is approx. EUR 502m per trend.at [S12]. Der Standard via [S38] cites approx. EUR 500m for FY2030/31.

Balance sheet, cash flow and ratios (group). Total assets, cash, debt split, net debt, equity, goodwill, working capital, operating cash flow, capex, FCF, ROE/ROA/ROIC, liquidity and leverage ratios, interest coverage and cash conversion cycle are all n/d in public summary sources. Known capital-structure facts:

  • 7.5% growth bond 2024–2029 [S28].

  • "Wachstumsanleihe III" fully placed early in July 2026 [S8]. A press headline refers to a EUR 20m bond being oversubscribed [S39].

  • Equity raise of approx. EUR 18m in fresh capital per the company listing release [S20]. Other outlets cite approx. EUR 25m [S23][S36]. EUR 25m was the maximum upsized volume; the company's own "almost EUR 18m" is preferred.

  • Credit agency KSV1870 assesses default probability at 0.19% (as of 2024) [S28].

  • Management says the 2030 target requires no further investment in production capacity [S23].

Commentary.

Growth: Growth accelerated to +44% in FY2024/25. Drivers were Austrian e-commerce (+99%) and international expansion (Germany, PLAZAs) [S6]. Guidance of approx. EUR 150m for FY2025/26 implies roughly +20%, a deceleration in percentage terms.

Profitability: EBITDA margin of approx. 15% is respectable. The steep drop to an EBIT margin of approx. 7% and a net margin of approx. 1.5% indicates heavy depreciation (owned production, Good Health World, PLAZA build-outs) and material financing costs from the 7.5% coupon bonds and community loans. These cost lines are inferred, since line items are n/d.

Inflection: The 2026 equity raise and listing mark a shift from debt-heavy retail financing toward equity. The step-change in channel strategy (pharmacy entry from October 2026) is the key operating inflection.

BIOGENA GROUP INVEST AG (standalone holding; FY ends 31 Jan)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleOwnership / note

Biogena Good Vibes AG

Top holding of the BIOGENA GROUP. Listed 10 Sep 2026

Majority founder/family-owned. Approx. 18% free float at listing

Biogena International

International sales

100% within the new holding

Austrian sales subsidiary (BIOGENA GmbH & Co KG and related entities)

Austrian operations and sales. Issuer of the growth bonds

Group Invest holds approx. 4% (press)

Biogena Group Invest AG

Listed minority holding vehicle

Merging into Good Vibes

Biogena Management Holding GmbH

Vehicle for strategic minority investments (e.g., HEROSAN 13.7%)

Group entity

BIOGENA One World Foundation

Charitable foundation (children's equal opportunities, environment, education)

Associated foundation

Business Lines

Business line (as named by the company)Content

BIOGENA core micronutrients

Pure-substance preparations (iron, minerals, osteoporosis focus)

BIOGENA ONE

Daily all-in-one routine product. Relaunched Aug 2026

BIOGENA Aesthetics

Beauty-from-within line

BIOGENA Sports

Sports nutrition / performance

Biohacking, Diagnostics & PLAZAs

Diagnostics, cold saunas, oxygen chambers, treatments

Workplace health promotion

Integrated B2B corporate health solutions

BIOGENA PETS

Animal micronutrients (now linked to HEROSAN)

BIOGENA Academy

Practitioner and consumer education

Segment Overview

SegmentFY2024/25

Group total revenue (EUR Mn)

124.9

Income Statement and Margin Analysis (%)

MetricFY2024/25

Revenue (EUR Mn)

124.9

Revenue growth YoY (%)

44

EBITDA (EUR Mn)

19.08

EBIT (EUR Mn)

8.54

Net income (EUR Mn)

1.82

EBITDA margin (%)

15.3

EBIT margin (%)

6.8

Net margin (%)

1.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2025/26 (guidance)FY2027/28 (earlier target)FY2029/30–2030/31 (Vision 2030)

Group revenue (EUR Mn)

150205500

Income Statement and Per-Share Data

MetricFY2023/24FY2025/26

Revenue / participation income (USD K, aggregator, n/v)

—402

EBITDA (USD K, aggregator, n/v)

—340

Net income (USD K, aggregator, n/v)

—336

Dividend per share (EUR)

0.030.05

Shares outstanding (m, derived)

—3.99

Revenue by Region

Region (EUR Mn)FY2024/25FY2025/26FY2029/30

Germany revenue (plan/target)

—58.0335.5

Group total revenue

124.9150500

Share Price History

DatePriceContext

Jul 2025

2.38

52-week / multi-year low

Mid/late Jun 2026

3.32–3.44

52-week high; YTD approx. +11%

Jun/Jul 2026

4.70

52-week high at the end of subscription; market cap EUR 17.72m

Late Jul 2026

5.30–5.35

After the capital raise

Aug 2026

5.20–5.40

YTD approx. +76%

25 Sep 2026

5.35

YTD approx. +81%

28 Sep 2026

5.25

EGM day; YTD approx. +78%

Margin Analysis (%)

Metric2026 YTD

Share price change (%)

78

Capital Markets

ItemValue

Exchange ratio

0.879197 Good Vibes shares per Group Invest share

Group Invest per-share value used in the merger

approx. EUR 4.39

Good Vibes per-share value used in the merger

approx. EUR 4.99

Look-through value at the Good Vibes day-one close (EUR 5.65)

approx. EUR 4.97 per Group Invest share

Group Invest close on 28 Sep 2026

EUR 5.25

Valuation Snapshot

MultipleValueBasis

Equity value / Sales

3.9x

486 / 124.9

Equity value / EBITDA

25.5x

486 / 19.08

P/E

267x

486 / 1.82

Equity value / FY2025/26E sales

3.2x

486 / 150

Capital Instruments

InstrumentIssuerCouponMaturitySize

Wachstumsanleihe 2024–2029

BIOGENA operating company

7.5%2029—

Wachstumsanleihe III

BIOGENA GmbH & Co KG

——

approx. EUR 20m (headline: oversubscribed)

Community financing (16 rounds since 2015)

Group

——

EUR 17m cumulative

Analyst Conclusions

Management guidance:

  • FY2025/26 (to 30 Sep 2026) group revenue of approx. EUR 150m (about +20%) [S10][S38].

  • Approx. EUR 500m by 2030 (FY2030/31 per Der Standard) [S38].

  • Germany to reach EUR 335.5m by FY2029/30 [S38b].

  • No profit guidance.

Consensus: none available.

Bull case:

  1. Proven compounding with operating leverage ahead. BIOGENA grew 44% in FY2024/25 at a 15% EBITDA margin. Management says the 2030 target needs no new production capacity [S23]. Depreciation-heavy EBIT and net margins could therefore widen sharply as volume runs through the existing plant.

  2. Pharmacy entry is a step-change in addressable market. By management's own description, BIOGENA has so far been absent from the main supplement channel [S23]. Even modest shelf share in Germany, Austria and Italy could add revenue faster than D2C alone.

  3. Germany flywheel. The PLAZA openings, Bundesliga partnerships and approx. EUR 58m Germany base [S6][S20][S34] create a credible platform for the planned 54% CAGR there.

Bear case:

  1. Valuation already discounts success. At EUR 486m the group trades at approx. 25x trailing EBITDA and approx. 267x trailing net income. Those are growth-stock multiples for a company with a 1.5% net margin.

  2. Funding intensity and leverage opacity. Repeated retail bonds (including at 7.5%) and community loans, combined with no published balance sheet or cash flow, mean leverage and free cash flow cannot be assessed.

  3. Execution and channel conflict. Quadrupling revenue in about five years while launching pharmacies, rolling out PLAZAs and entering pets risks overstretching a founder-centric organisation of about 480 staff.

Catalysts and monitorables (next 12 months):

  • Firmenbuch registration, the last Group Invest trading day, and crediting of Good Vibes shares (Q4 2026 expected [S30]).

  • FY2025/26 results versus the approx. EUR 150m guidance, including the first full-year disclosure as a listed group holding.

  • Pharmacy-channel sell-in in AT/DE/IT (from Oct 2026).

  • Frankfurt PLAZA opening and Munich utilisation.

  • Any refinancing of high-coupon debt with the new equity.

  • Possible move to a higher-tier market segment [S23].

  • Contribution from the HEROSAN and Combyn investments.

Analyst verdict. Biogena Group Invest AG is no longer an investment case in its own right. It is a short-lived conversion instrument. Shareholders unanimously approved its absorption into Biogena Good Vibes AG at 0.879197 new shares per share, and the company is expected to disappear from the register and the exchange once the Firmenbuch entry occurs. Management guides that for Q4 2026, while one outlet suggests early 2027.

Anyone holding or analysing the BIO.VI line should therefore look through to Good Vibes, and two things follow. First, at the late-September close of EUR 5.25, Group Invest traded above the merger's own valuation of approx. EUR 4.39 per share. It also traded at or slightly above its look-through value at Good Vibes' debut close. Arbitrage upside appears limited, and Group Invest's thin liquidity adds friction.

Second, the underlying BIOGENA franchise is genuinely attractive. It is Austria's market leader, vertically integrated, practitioner-endorsed, growing 40%-plus with a loyal customer-shareholder base, and about to unlock the pharmacy channel.

The tension lies in price and transparency. A EUR 486–550m valuation equals roughly 4x sales and 25x EBITDA on a business that converted only about 1.5% of revenue into net profit in FY2024/25. That business has financed itself partly through 7.5% retail bonds, and the direct market plus regime does not oblige it to publish full balance-sheet and cash-flow detail. The Vision 2030 target of EUR 500m is ambitious: it requires about 32% compound growth and a sixfold scale-up in Germany.

Our synthesis is that the operating story merits attention, but the equity is priced for flawless execution and should be underwritten only after the first full-year listed disclosure. That disclosure needs to show debt, cash generation and early pharmacy traction. For Group Invest holders, the practical decision is simply whether to accept Good Vibes exposure through conversion or to exit before the last trading day. Neutral, high-uncertainty stance; key watch items are FY2025/26 results and the merger registration date.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleEntityTenurePrior roles / education

Dr. Albert Schmidbauer

Founder and CEO, BIOGENA GROUP

Group / Good Vibes AG

Since founding 2006

Holds a doctorate (field n/d). Founder

Stefan Klinglmair

CEO / Management Board, Biogena Group Invest AG; IR contact; member of group management board

Group Invest AG / Group

n/d (led the uplisting)

—

Julia Hoffmann

Member of group management board

Group

——

Supervisory Board members

—

Both AGs

——

Competitive Landscape

Key Competitors

CompetitorSegment overlapOwnershipRelative positioning vs BIOGENA

Pure Encapsulations

Practitioner-channel premium supplements

Nestlé Health Science

Global hypoallergenic, practitioner-led brand with much greater scale. Closest model analogue

Orthomol

Premium micronutrient combinations, pharmacy-led

Private (Germany)

Dominant in German pharmacies, the channel BIOGENA is entering

Doppelherz (Queisser Pharma)

Mass-market supplements, pharmacy and drugstore

Private (Germany)

Mass-market leader; lower price point

Burgerstein (Antistress AG)

Premium micronutrients, pharmacy

Private (Switzerland)

DACH premium pharmacy peer

Dr. Böhm (Apomedica)

Supplements, Austrian pharmacies

Private (Austria)

Austrian pharmacy-channel leader

Sunday Natural

D2C premium natural supplements

Private (Germany)

Online D2C competitor in Germany

Bayer Consumer Health (e.g., Supradyn, Elevit)

Vitamins and minerals

Bayer AG (listed)

Global scale and pharmacy power

Haleon (Centrum)

Multivitamins

Haleon plc (listed)

Global mass-market leader

dm-drogerie markt (Mivolis, private label)

Mass-market supplements

Private

Price competition in DACH drugstores

Thorne

Premium science-based supplements, practitioner and D2C

Private (L Catterton)

US premium peer with an international push

Peer Comparison FY2024

MetricBIOGENA (FY2024/25)Pure Encapsulations

Revenue

EUR 124.9m [S12]

n/d (not separately reported)

Revenue growth

+44% [S6]

—

EBITDA margin

approx. 15.3% (calculated)

—

Company Snapshot

$135.2M

Revenue

2020

Founded

Salzburg, Austria

Headquarters

SWOT Analysis

Strengths

  • Strong growth: +44% revenue growth in FY2024/25 to approx. EUR 124.9m [S6][S12]
  • Long-run compounding: About 27% average annual growth since founding; revenue from EUR 1.4m in 2006 [S28][S6]
  • Profitable at EBITDA level: EBITDA approx. EUR 19.1m, about 15% margin [S12]
  • Vertical integration: Own Austrian production; about 260 products free of colourants and preservatives [S28]
  • Science credentials: In-house team of about 25 scientists; seven Market-Test wins in 2025 [S28][S6]
  • Loyal community: More than 2,300 new shareholders in the 2026 raise; more than EUR 17m community financing since 2015; more than 90% recommendation rate [S20][S19][S6]
  • Digital traction: Austrian e-commerce +99% in FY2024/25 [S6]

Weaknesses

  • Thin bottom line: Net income approx. EUR 1.82m on approx. EUR 125m revenue (approx. 1.5%) [S9][S12]
  • Large EBITDA-to-EBIT gap: EBIT of EUR 8.54m vs EBITDA of EUR 19.08m implies heavy D&A [S10]
  • Expensive debt: 7.5% coupon growth bond 2024–2029 [S28]
  • Limited disclosure: Direct market plus has relaxed reporting [S23]; no segment, balance-sheet or cash-flow data publicly summarised
  • Key-person concentration: Founder-CEO and majority owner [S21]
  • Low liquidity: Group Invest market cap approx. EUR 18–21m; trades as small as single-digit trade counts [S11][S3]
  • No pharmacy presence until Oct 2026: Management concedes absence from the main channel [S23]

Opportunities

  • Germany scale-up: Plan from EUR 58.0m to EUR 335.5m by FY2029/30 [S38b]
  • Pharmacy channel: Entry in AT, DE and IT from Oct 2026 [S23]
  • PLAZA roll-out: Düsseldorf open; Munich opened Sep 2026; Frankfurt planned [S6][S20]
  • Operating leverage: EUR 500m target without new production capacity [S23]
  • Adjacencies: Pets (HEROSAN 13.7%), MedTech (Combyn) [S33][S34]
  • Capital-markets upgrade: Founder signals ambitions beyond direct market plus [S23]
  • Brand reach via sport: Bayer 04 Leverkusen and Fortuna Düsseldorf partnerships [S34][S35]

Threats

  • Execution risk of fourfold growth: 125 to 500 by 2030 implies approx. 32% CAGR [S10]
  • Incumbent pharmacy brands: Orthomol and Burgerstein are entrenched in DACH pharmacies (industry structure)
  • Valuation risk: EUR 486m merger value equals approx. 25x FY2024/25 EBITDA and approx. 267x net income (calculated from [S30][S12][S9])
  • Retail cost inflation: PLAZA build-outs are capex- and lease-intensive (inferred)
  • Regulatory: EU health-claims and novel-food regimes (sector-wide)
  • Merger timing: Registration timing open; "Q4 2026" [S30] vs "early 2027" [S22]
  • Consumer cyclicality: Premium discretionary health spend (sector-wide)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jul 2025Group Invest shares bottom at EUR 2.38 [S11]Low base for the 2026 rally
7 Oct 2025Group Invest capital-market release (content n/d) [S16]Disclosure cadence
Oct 2025Düsseldorf PLAZA opens (1,000 m²) [S6]First large German flagship
17 Oct 2025Group Invest capital-market release (content n/d) [S16]—
31 Oct 2025Group Invest capital-market release (content n/d) [S16]—
Nov 2025WKO reports +44% growth in FY2024/25; e-commerce +99%; seven Market-Test wins [S6]Validates momentum
5 Mar 2026AGM documents for FY2025/26 (to 31 Jan 2026) published [S27]Governance
24 Mar 2026Full-year results of Group Invest published [S27]Reporting
26 Mar 20267th ordinary AGM in Koppl; appropriation of profit [S27][S19]Dividend (EUR 0.05 announced for FY2025/26)
13–14 May 2026Group Invest announces review of structural measures / merger [S16][S36]Start of restructuring
10 Jun 2026Good Vibes announces off-exchange capital increase [S13][S37b]Pre-IPO funding
16 Jun 2026Public offer starts (4,164,064 base shares; upsize to about 5.2m) [S36]—
Jun 2026Group Invest hits 52-week high of EUR 3.44, later EUR 4.70 [S13][S11]Market anticipates the merger
10 Jul 2026Fortuna Düsseldorf partnership [S35]German brand building
21 Jul 2026Group Invest supervisory board appoints joint merger auditor [S15][S16]Merger preparation
21 Jul 2026Media report the listing plan, EUR 475m offer valuation and 480+ employees [S4]Public visibility
22 Jul 2026Subscription closes; about 2,300–2,500 new shareholders [S20][S37]Broader base
Jul 2026Wachstumsanleihe III fully placed early [S8]Debt funding secured
10 Aug 2026Bayer 04 Leverkusen partnership official [S34]German brand reach
11 Aug 2026BIOGENA ONE new formula and brand [S34]Product refresh
18 Aug 2026EUR 800 holiday-care bonus per child for employees [S37b]Employer branding
19 Aug 2026Investment in Combyn Health Care [S34]MedTech option
24 Aug 202613.7% stake in HEROSAN [S33]Pet-health expansion
27 Aug 2026Draft merger agreement signed; ratio 1:0.879197; H1 2026 report; BDO confirms ratio as adequate [S30]Key terms fixed
10 Sep 2026Good Vibes first trading day: ref EUR 4.80, close EUR 5.65 (+17.7%), high EUR 6.45; market cap approx. EUR 550m [S20][S22]Successful debut. Originally planned for 27 Aug; slipped by two weeks
Sep 2026Munich PLAZA opens [S20]Germany expansion
17 Sep 2026Great Place To Work: #64 among Best Small & Medium Workplaces in Europe 2026 [S34]Employer brand
28 Sep 2026Both EGMs approve the merger unanimously [S31][S29]Final shareholder approval
30 Sep–2 Oct 2026Company says registration date, exchange mechanics and last trading day will follow [S29][S31]Timeline open
Early Oct 2026Der Standard: only Good Vibes will remain listed; FY2025/26 revenue approx. EUR 150m; approx. EUR 500m by FY2030/31 [S38]Confirms end-state
Oct 2026 (planned)Pharmacy-channel launch in AT/DE/IT [S23]Major channel step

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Group total revenue was EUR 124.9 Mn in FY2024/25.
Biogena Group Invest Ag — Revenue by Segment
Series (EUR Mn)FY2024/25
Group total revenue124.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Wiener Börse: Biogena Group Invest moves up into direct market plus (wienerborse.at)
  2. S2Wiener Börse: First trading day of Biogena Group Invest in the direct market (wienerborse.at)
  3. S3Wiener Börse instrument page ATBIOGENA005 (wienerborse.at)
  4. S4Salzburg24, 21 Jul 2026 (salzburg24.at)
  5. S5Börse Express: Pharma-Aktien … Biogena vor Wiener Notierung (boerse-express.com)
  6. S6WKO Salzburg, Nov 2025 (wko.at)
  7. S7Kapitalmarktexperten: Fusion mit Good Vibes geprüft (kapitalmarktexperten.de)
  8. S8Trading-Treff: 27. August für Börsenstart geplant (trading-treff.de)
  9. S9Trading-Treff: Verschmelzung noch 2026 geplant (trading-treff.de)
  10. S10Trading-Treff: 500 Millionen Euro bis 2030 (trading-treff.de)
  11. S11Trading-Treff: 52-Wochen-Hoch bei Zeichnungsfrist-Ende (trading-treff.de)
  12. S12trend.at: Qualität "Made in Austria" (trend.at)
  13. S13Trading-Treff: 52-Wochen-Hoch bei 3,44 Euro (trading-treff.de)
  14. S14Trading-Treff: 27. August mit Börsenstart (trading-treff.de)
  15. S15Kapitalmarktexperten: Handelsstart am 27. August (kapitalmarktexperten.de)
  16. S16pressetext PTA release, 16 Apr 2024 (with list of later releases) (pressetext.com)
  17. S17Salzburg24 (prospectus figures) (salzburg24.at)
  18. S18pressetext PTA release, 22 Jan 2024 (pressetext.com)
  19. S19Trading-Treff: 17,5 Prozent Rallye pausiert (trading-treff.de)
  20. S20news.at / BIOGENA press release: Good Vibes starts trading (first trading day 10 Sep 2026) (news.at)
  21. S21BIOGENA press: Good Vibes AG startet Handel (biogena.com)
  22. S22Trending Topics: Aktie am ersten Tag 17,7% im Plus (trendingtopics.eu)
  23. S23Trending Topics: 470 Mio. Bewertung / Startbase listing coverage · startbase.de
  24. S24multiples.vc: Biogena Good Vibes (aggregator) (multiples.vc)
  25. S25multiples.vc: Biogena Group Invest (aggregator) (docs.multiples.vc)
  26. S26ad-hoc-news: Hauptversammlung stimmt Fusion ab (ad-hoc-news.de)
  27. S27Börse Express: Weichenstellung naht (AGM 2026) (boerse-express.com)
  28. S28die macher: 7.5% growth bond profile (diemacher.at)
  29. S29boerse-social.com, 30 Sep 2026 (boerse-social.com)
  30. S30Ad-hoc release (Art. 17 MAR), 27 Aug 2026: merger information (a.storyblok.com)
  31. S314investors: Aktionäre stimmen Verschmelzung zu; finanznachrichten PTA (Good Vibes EGM) · finanznachrichten.de
  32. S32finanznachrichten: PTA Group Invest EGM approval and prior releases (finanznachrichten.de)
  33. S33BIOGENA press: invests in HEROSAN (biogena.com)
  34. S34BIOGENA press room (GPTW, Combyn, BIOGENA ONE, Bayer 04) (biogena.com)
  35. S35BIOGENA press room (Fortuna Düsseldorf, HEROSAN, offer) (biogena.com)
  36. S36ad-hoc-news: Verschmelzung an 27. August geknüpft; Börse Global: 4,803 Euro für neue Aktien · boerse-global.de
  37. S36btrend.at: BIOGENA vor dem nächsten Wachstumsschritt (trend.at)
  38. S37Börse Global: 2.500 neue Aktionäre (boerse-global.de)
  39. S37bBIOGENA press room (bees, childcare bonus) (biogena.com)
  40. S38Börse Global: Die Fusion wird Realität! (citing Der Standard) (boerse-global.de)
  41. S38bKapitalmarktexperten: 75% Gewinn seit Jahresbeginn (Germany plan) (kapitalmarktexperten.de)
  42. S39stock-world: Verschmelzung mit Good Vibes besiegelt (bond headline) (stock-world.de)
  43. S40sustainabilityreports.com: Biogena Group Invest filings index (sustainabilityreports.com)
  44. S41Trading-Treff: Good Vibes Fusion kommt zur Abstimmung (trading-treff.de)
  45. S42ad-hoc-news: Aktionäre entscheiden am 28. September (ad-hoc-news.de)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.